Safety Pharmacology

WuXi AppTec’s Safety Pharmacology group profiles compounds for potential adverse drug reactions at various R&D stages, thereby helping to deliver high-quality drug candidates faster and at lower cost.

Electrophysiology

The state-of-the-art automated QPatch-HT system (48 channels) enables higher throughput, lower cost, and better consistency for hERG channel recordings.
  • Provides integrated risk assessment on cardiosafety for compounds at various discovery and development stages on hERG and other cardiac ion channels.
  • The state-of-the-art automated QPatch- HT system (48 channels) enables higher throughput, lower cost, and better consistency for hERG channel recordings.
  • Conventional patch clamp assay and tissue level recording (e.g., on Purkinje fiber or isolated heart) provides detailed mechanistic information for compounds identified with QPatch.
    • Automated Patch Clamp
      • QPatch assay for hERG as a safety target
      • QPatch assay for other cardiosafety channels
    • Conventional Patch Clamp
      • MOA studies for lead compounds
      • Tissue level recording
      • GLP hERG assay provides quality data for registration purposes

In vitro Pharmacology

  • Addresses off-target based adverse drug reactions (ADR) and promiscuity of compounds. Such information may help guide compounds of interest through downstream in vivo tests for potential liabilities.
    • Biochemical Assay
      • Receptor ligand binding assays
      • Kinase and protease assays
    • Cell-based Assay
      • FLIPR (Ca or Membrane Potential) based assays for ion channels or transporters
      • FLIPR or GTPy_S assay for functional GPCRs

Early Toxicology

  • Provides an early warning on potential genotoxicity for compounds during lead optimization. These assays are predictive of the GLP development full-panel Ames test as well as in vivo Micronucleus test, but with lower compound consumption and faster turnaround.
    • Genotoxicity Assay
      • Mini-Ames
      • High-content Micronucleus